Results 61 to 70 of about 438,171 (330)

Regulation of disease signaling by YOD1: potential implications for therapeutic strategies

Cancer Cell International
YOD1 (OTUD2) is a pivotal deubiquitinating enzyme (DUB) of the Otubain family. It plays an essential role in protein degradation and the regulation of cell signal transduction, influencing various biological processes.
Jiawei Zhao, Xiaotong Guo, Houzhong Li, Yujing Chen, Jingjing Du, Juzheng Zhang, Jinfeng Gan, Peitao Wu, Siqi Chen, Xinwen Zhang, Jinfeng Yang, Jiamin Jin   +11 more
doaj   +1 more source

Immunology of Oral Squamous Cell Carcinoma—A Comprehensive Insight with Recent Concepts

Life, 2022
This review aims to understand the concept of oral cancer immunology through the notion of immune profiling, immunoediting and immunotherapy, and to gain knowledge regarding its application for the management of oral cancer patients.
Sowmya Samudrala Venkatesiah, Dominic Augustine, Deepika Mishra, Neethi Gujjar, Vanishri C. Haragannavar, Kamran Habib Awan, Shankargouda Patil   +6 more
doaj   +1 more source

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

Molecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He, Chiara Testini, Neda Hekmati, Altea Bonello, Aglaia Schiza, Emmanuel Nwadozi, Mia Phillipson, Carina Strell, Michael Welsh   +8 more
wiley   +1 more source

Optineurin functions for optimal immunity [PDF]

, 2018
Optineurin (OPTN) was identified 20 years ago in a yeast-two-hybrid screen with a viral protein known to inhibit the cytolytic effects of tumor necrosis factor.
Slowicka, Karolina, van Loo, Geert
core   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer

Scientific Reports, 2022
Regulatory T cells (Tregs) suppress the host immune response and maintain immune homeostasis. Tregs also promote cancer progression and are involved in resistance to immune checkpoint inhibitor treatments.
Miya Haruna, Azumi Ueyama, Yoko Yamamoto, Michinari Hirata, Kumiko Goto, Hiroshi Yoshida, Naoko Higuchi, Tetsuya Yoshida, Yujiro Kidani, Yamami Nakamura, Morio Nagira, Atsunari Kawashima, Kota Iwahori, Yasushi Shintani, Naganari Ohkura, Hisashi Wada   +15 more
doaj   +1 more source

Fighting viral infections and virus-driven tumors with cytotoxic CD4+ T cells [PDF]

, 2017
CD4+ T cells have been and are still largely regarded as the orchestrators of immune responses, being able to differentiate into distinct T helper cell populations based on differentiation signals, transcription factor expression, cytokine secretion, and
Adhikary, Adhikary, Adhikary, Ahn, Anderson, Annunziato, Appay, Appay, Aslan, Balfour, Battaglia, Baumjohann, Bickham, Bosselut, Britt, Brown, Brown, Brown, Brown, Brown, Bui, Cao, Cao, Cao, Carpenter, Casazza, Chen, Cheroutre, Chiu, Coler, de Souza, Deligeoroglou, Demachi-Okamura, Depil, Devarajan, Di Mitri, Dillon, Draenert, Duftner, Dumitriu, Endo, Enssle, Eshima, Facchinetti, Farrar, Faè, Fishman, Fleischer, Fontenot, Freeman, Fu, Fu, Gamadia, Gao, Garcia-Chagollan, Gasser, Geginat, Gelband, Goonetilleke, Grabowska, Grakoui, Grant, Grant, Groh, Ha, Haigh, Haque, Heaton, Hegde, Heller, Heusinkveld, Hildemann, Hislop, Hohler, Homma, Houser, Hua, Huz, Icheva, James, Jameson, Jeitziner, Johnson, Jones, Jones, Jonjic, Kadish, Kannanganat, Kaufmann, Kayagaki, Kenter, Kenter, Khanolkar, King, King, Kobayashi, Koel, Krensky, Kroesen, Kruger, Kuroda, Lazdina, Li, Libri, Lin, Loewendorf, Long, Long, Long, Long, Luckheeram, Lunemann, MacArthur, Mackay, Magnani, Malnati, Man, Manzke, Marshall, Martorelli, Mattapallil, McKinstry, McMichael, Merlo, Merlo, Metkar, Miamen, Moormann, Morales, Mosmann, Mucida, Munz, Munz, Murphy, Musey, Namekawa, Nemes, Nikiforow, Nixon, Norris, Oestreich, Omiya, O’Shea, Pachnio, Pachnio, Paludan, Pender, Peng, Penna, Piriou, Plata, Porakishvili, Qui, Quigley, Ratto-Kim, Reis, Rentenaar, Rerks-Ngarm, Ressing, Rosenberg, Sacha, Sakaguchi, Sallusto, Sandbulte, Savic, Scherrenburg, Schueller, Schulze zur Wiesch, Schulze Zur Wiesch, Schwartz, Seresini, Seresini, Soghoian, Soghoian, Spaete, Stacey, Steele, Streeck, Stuller, Su, Sun, Tagawa, Takeuchi, Tenzer, Terahara, Tewari, Thursz, Todryk, Tong, Toussirot, Trautmann, Trautmann, Trifari, Tscharke, Turnbull, Ulsenheimer, Vacchio, van de Berg, van den Hende, van Leeuwen, Vasin, Veldhoen, Ventura, Verma, Veronese, Voo, Voo, Vossen, Walker, Walton, Wang, Wang, Welters, Welters, WHO, Wilkinson, Wilson, Wilson, Wintermeyer, Workman, Xie, Xue, Yan, Yewdell, Zaunders, Zaunders, Zheng, Zhou, Zuo, zur Hausen   +229 more
core   +2 more sources

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Arachidonic acid impairs natural killer cell functions by disrupting signaling pathways driven by activating receptors and reactive oxygen species

Cell Communication and Signaling
Background High levels of the polyunsaturated fatty acid arachidonic acid (AA) within the ovarian carcinoma (OC) microenvironment correlate with reduced relapse-free survival.
Mohamad K. Hammoud, Celina Meena, Raimund Dietze, Nathalie Hoffmann, Witold Szymanski, Florian Finkernagel, Andrea Nist, Thorsten Stiewe, Johannes Graumann, Elke Pogge von Strandmann, Rolf Müller   +10 more
doaj   +1 more source

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

Molecular Oncology, EarlyView.
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui, Matthew A. Cottam, Muhammad Bilal Mirza, Keeli B. Lewis, Kristen K. Ciombor, Mary Kay Washington, Kamran Idrees   +6 more
wiley   +1 more source